Selected Grants
A phase 3, randomized, double-masked, placebo-controlled, efficacy, safety, and tolerability study of VRDN-003 in participants with active thyroid eye disease (TED)
Clinical TrialPrincipal Investigator · Awarded by Viridian Therapeutics · 2025 - 2030A phase 3, randomized, double-masked, placebo-controlled, efficacy, safety, and tolerability study of VRDN-003 in participants with chronic thyroid eye disease (TED)
Clinical TrialPrincipal Investigator · Awarded by Viridian Therapeutics · 2025 - 2030PROSPECTIVE PEDIATRIC PSEUDOTUMOR CEREBRI SYNDROME STUDY (PPTS)
ResearchPrincipal Investigator · Awarded by Children's Hospital of Philadelphia · 2024 - 2026Ultracompact Hand-held Swept-Source Hand-Held Optical Coherence Tomography (SS-HH-OCT) as a Novel Diagnostic Modality for Early-Onset Retinal Dystrophies (EORDs)
ResearchCollaborator · Awarded by Foundation Fighting Blindness, Inc · 2023 - 2026Secondary Data Analysis for Neonates with Retinal OCT Imaging
ResearchCo Investigator · Awarded by National Institutes of Health · 2022 - 2025Portable motion-stabilized optical coherence tomography for eye care in acute care settings
ResearchCo Investigator · Awarded by National Institutes of Health · 2018 - 2022Using Optical Coherence Tomography to Elucidate Optic Nerve Development in Healthy Infants and Children
ResearchPrincipal Investigator · Awarded by Knights Templar Eye Foundation, Inc. · 2015 - 2017External Relationships
- Alexion Pharmaceuticals, Inc. a subsidiary of AstraZeneca
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.